Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial - Concepedia

Concepedia

Publication | Open Access

Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial

DOI Full Paper Access

50

Citations

24

References

2022

Year

Lukáš Rob, David Cibula, Paweł Knapp, Peter Mallmann, Jaroslav Klát, Luboš Minář, Pavel Bartoš, Josef Chovanec, Petr Valha, Marek Pluta,

Journal for ImmunoTherapy of Cancer

Abstract

NCT02107937, EudraCT2010-021462-30.

References

	Year	Citations

Page 1